Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kenvue Inc (KVUE)

Kenvue Inc (KVUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

How Is Kenvue’s Stock Performance Compared to Other Consumer Staple Stocks?

Headquartered in Summit, New Jersey, Kenvue Inc. (KVUE) is a global consumer health company focused on everyday health and personal care products. With a market cap of roughly $34.8 billion, the company sits in the “large-cap” bracket, a category typically reserved for businesses valued above $10 billion. The scale gives Kenvue the reach and resources to maintain a portfolio that spans a broad spectrum of daily health needs.

It sells over-the-counter treatments for cough, cold, allergies, pain relief, and digestive health, while also offering products across skincare, haircare, oral care, and baby care. Its lineup features household brands such as Tylenol, Benadryl,...

Fundamentals

See More
  • Market Capitalization, $K 34,424,504
  • Shares Outstanding, K 1,916,732
  • Annual Sales, $ 15,124 M
  • Annual Income, $ 1,470 M
  • EBIT $ 2,414 M
  • EBITDA $ 2,971 M
  • 60-Month Beta 0.51
  • Price/Sales 2.30
  • Price/Cash Flow 13.17
  • Price/Book 3.23

Options Overview Details

View History
  • Implied Volatility 23.84% (-2.50%)
  • Historical Volatility 20.71%
  • IV Percentile 9%
  • IV Rank 10.60%
  • IV High 92.41% on 12/03/25
  • IV Low 15.71% on 05/28/25
  • Expected Move (DTE 2) 0.31 (1.77%)
  • Put/Call Vol Ratio 0.62
  • Today's Volume 946
  • Volume Avg (30-Day) 11,950
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 619,920
  • Open Int (30-Day) 646,131
  • Expected Range 17.43 to 18.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.26
  • Number of Estimates 3
  • High Estimate 0.27
  • Low Estimate 0.26
  • Prior Year 0.24
  • Growth Rate Est. (year over year) +8.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.60 +0.62%
on 03/11/26
19.18 -7.66%
on 02/27/26
-0.83 (-4.48%)
since 02/11/26
3-Month
16.56 +6.98%
on 01/07/26
19.18 -7.66%
on 02/27/26
+0.39 (+2.25%)
since 12/11/25
52-Week
14.02 +26.32%
on 10/30/25
25.17 -29.64%
on 05/08/25
-5.78 (-24.61%)
since 03/11/25

Most Recent Stories

More News
How Is Kenvue’s Stock Performance Compared to Other Consumer Staple Stocks?

While recent performance trails the industry, Kenvue continues to retain measured analyst confidence and long-term relevance.

KVUE : 17.69 (-1.50%)
XLP : 84.59 (-1.32%)
CHD : 99.30 (-1.81%)
Kenvue: Q4 Earnings Snapshot

Kenvue: Q4 Earnings Snapshot

KVUE : 17.69 (-1.50%)
Kenvue Reports Fourth Quarter and Full Year 2025 Results

Q4 Net Sales 3.2%; Organic Sales 1 1.2% Q4 Diluted EPS was $0.17; Adjusted Diluted EPS 1 ...

KVUE : 17.69 (-1.50%)
What Are Wall Street Analysts' Target Price for Kimberly-Clark Stock?

Analysts continue to back Kimberly-Clark despite its recent stock lag, signaling confidence in its longer-term fundamentals.

KMB : 100.05 (-1.63%)
BAC : 48.33 (-0.47%)
$SPX : 6,762.72 (-0.28%)
KVUE : 17.69 (-1.50%)
XLP : 84.59 (-1.32%)
Kenvue to Announce Fourth Quarter and Full Year 2025 Results on February 17, 2026

Kenvue Inc. (NYSE: KVUE) will announce its fourth quarter and full year 2025 financial results after market close on February 17, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not...

KVUE : 17.69 (-1.50%)
1 Dividend King to Buy and Hold Through Any Market

In uncertain markets, reliable income matters more than ever. This Dividend King offers exactly that.

$SPX : 6,762.72 (-0.28%)
JNJ : 242.37 (-0.55%)
KVUE : 17.69 (-1.50%)
Kimberly-Clark and Kenvue Shareholders Overwhelmingly Approve Kimberly-Clark's Acquisition of Kenvue

Key Milestone in Creating a Global Health and Wellness Leader

KMB : 100.05 (-1.63%)
KVUE : 17.69 (-1.50%)
Kenvue Is Headed for a Merger Vote on January 29. How Should You Play KVUE Stock Here?

KVUE stock could gain 15% this week if the potential merger with Kimberly-Clark is approved by all major stakeholders.

KMB : 100.05 (-1.63%)
JNJ : 242.37 (-0.55%)
KVUE : 17.69 (-1.50%)
Kenvue Stock: Analyst Estimates & Ratings

As Kenvue has underperformed the broader market over the past year, Wall Street analysts maintain a cautious outlook about the stock’s prospects.

KMB : 100.05 (-1.63%)
$SPX : 6,762.72 (-0.28%)
KVUE : 17.69 (-1.50%)
XLP : 84.59 (-1.32%)
Kenvue Declares Quarterly Cash Dividend

Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is payable on February 25, 2026, to shareholders...

KVUE : 17.69 (-1.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Kenvue Inc. is a pure-play consumer health company. Its brand portfolio includes AVEENO(R), BAND-AID(R) Brand Adhesive Bandages, JOHNSON'S(R), LISTERINE(R), NEUTROGENA(R), TYLENOL(R) and ZYRTEC(R). Kenvue Inc. is based in SKILLMAN, N.J.

See More

Key Turning Points

3rd Resistance Point 18.38
2nd Resistance Point 18.26
1st Resistance Point 18.11
Last Price 17.69
1st Support Level 17.84
2nd Support Level 17.72
3rd Support Level 17.57

See More

52-Week High 25.17
Fibonacci 61.8% 20.91
Fibonacci 50% 19.60
Fibonacci 38.2% 18.28
Last Price 17.69
52-Week Low 14.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar